Back to Journals » Journal of Multidisciplinary Healthcare » Volume 16
Evaluation of Patient Experience with a Model of Coordinated Telematic Pharmaceutical Care Between Hospital and Rural Pharmacies in Spain [Response To Letter]
Authors Morillo-Verdugo R , Morillo-Lisa R , Espolita-Suarez J, Delgado-Sanchez O
Received 25 April 2023
Accepted for publication 9 May 2023
Published 26 May 2023 Volume 2023:16 Pages 1473—1474
Ramón Morillo-Verdugo,1 Rosa Morillo-Lisa,2 Jaime Espolita-Suarez,3 Olga Delgado-Sanchez4
1Pharmacy Hospital Service, Hospital Valme, Área de Gestión Sanitaria Sur de Sevilla, Sociedad Española de Farmacia Hospitalaria, Sevilla, Spain; 2Rural Community Pharmacy, Sociedad Española de Farmacia Rural, Alcalá de Ebro, Zaragoza, Spain; 3Rural Community Pharmacy, Sociedad Española de Farmacia Rural, León, Spain; 4Pharmacy Hospital Service, Hospital Son Spases, Sociedad Española de Farmacia Hospitalaria, Palma de Mallorca, Spain
Correspondence: Ramón Morillo-Verdugo, Hospital de Valme, Avda/Bellavista s/n, Seville, CP: 41014, Spain, Tel +34 955015467, Email [email protected]
View the original paper by Dr Morillo-Verdugo and colleagues
This is in response to the Letter to the Editor
We thank to Kolomboy et al for their interest and comment of our paper.
We completely agree with your assessment that telepharmacy is a crucial component of modern healthcare, and it has the potential to improve patient experience and satisfaction significantly. The Capacity-Motivation-Opportunity (CMO) model introduced in this paper is a valuable contribution to the field of pharmaceutical care, and the study shows that it has been effective in improving patient experience in line with other studies that have shown its usefulness and impact on improving patient health outcomes.1,2
You rightly pointed out that would be some limitations to telepharmacy practice, such as the lack of direct patient education and counseling related to self-management and illness. It should not be forgotten that, according to the methodology we have developed, care is individualized for each patient (according to stratification models) and we work to achieve pharmacotherapeutic objectives individually and dynamically, which would largely solve this possible difficulty.
Privacy and security concerns also need to be addressed to ensure regulatory compliance and patient confidentiality. Indeed, this is a fundamental aspect that we have taken into account, both in the definition of telepharmacy itself and in its subsequent development within the conceptual framework. In addition, the tool developed complies with all the data protection regulations established in the Spanish regulatory framework.3,4
We appreciate your suggestion that post-hoc analysis should be conducted to determine the extent to which higher levels of education translate to better understanding of pharmaceutical services among patients. It is also important to provide support and training to pharmacists so that they can maintain their knowledge of modern telepharmaceutical procedures and offer pharmaceutical services effectively. This is an aspect that we would like to further develop in the future, when the number of patients allows us to carry out this type of analysis. We appreciate the feedback and will consider these suggestions for refining our methods in future research.
Finally, we agree with your conclusion that pharmacist associations should advocate for laws and regulations on telepharmacy to ensure patient safety, privacy, and legacy of telepharmacy education. It is imperative to create a strong, safe, and needs-based telepharmaceutical platform that can benefit patients directly. In Spain, through the MAPEX-SEFH project, this aspect has been under development for 8 years, and a set of documents aimed at providing this support to patients and professionals has recently been created.5 All this development has gone into the creation, development and application of the TELEMACO tool.
Thank you again for your insightful comments on this topic.
The authors report no conflicts of interest in this communication.
1. Morillo-Verdugo R, Lazaro-Lopez A, Alonso-Grandes E, et al. Patient experience evaluation of the CMO-based pharmaceutical care model vs usual care in people living with HIV. J Multidiscip Healthc. 2022;15:2991–3003. doi:10.2147/JMDH.S392398
2. Cantillana-Suárez MG, Robustillo-Cortés MLA, Gutiérrez-Pizarraya A, Morillo-Verdugo R. Impact and acceptance of pharmacist-led interventions during HIV care in a third-level hospital in Spain using the Capacity-Motivation-Opportunity pharmaceutical care model: the IRAFE study. Eur J Hosp Pharm. 2021;28(Suppl 2):e157–e163. doi:10.1136/ejhpharm-2020-002330
3. Morillo-Verdugo R, Margusino-Framiñán L, Monte-Boquet E, et al. Spanish Society of Hospital Pharmacy position statement on telepharmacy: recommendations for its implementation and development. Farm Hosp. 2020;44(4):174–181. English. doi:10.7399/fh.11515
4. Margusino-Framiñán L, Monte-Boquet E. Telepharmacy: usefulness, implantation and research. Farm Hosp. 2022;46(7):1–2.
5. Sociedad Española de Farmacia Hospitalaria [Spanish Society of Hospital Pharmacy]. Proyecto Mapex: marco Estratégico de Telefarmacia [página web] [Mapex Project: Telepharmacy Strategic Framework [web page]]. Madrid; 2020. Available from: https://www.sefh.es/mapex/cmo-oportunidad.php.
© 2023 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.